COMMUNIQUÉS West-GlobeNewswire
-
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
18/06/2026 -
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
18/06/2026 -
Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470
18/06/2026 -
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
18/06/2026 -
Legend Biotech Corporation Announces Pricing of Public Offering
18/06/2026 -
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
18/06/2026 -
Zelluna ASA: Private Placement and Retail Offering successfully placed
18/06/2026 -
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
18/06/2026 -
Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement
18/06/2026 -
Postponement and Re-scheduling of Annual General Meeting
17/06/2026 -
Premier Health of America Provides Update on Management Cease Trade Order
17/06/2026 -
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/06/2026 -
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
17/06/2026 -
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
17/06/2026 -
Publication relative à des notifications de transparence
17/06/2026 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/06/2026 -
Legend Biotech Corporation Announces Proposed Public Offering
17/06/2026 -
Nyxoah Receives $15 Million from the European Investment Bank
17/06/2026 -
Publication relating to transparency notifications
17/06/2026
Pages